Menu
GeneBe

rs730880685

Variant summary

Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong

The NM_000256.3(MYBPC3):c.913_914del(p.Phe305ProfsTer27) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000219 in 1,367,976 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000016 ( 0 hom. )

Consequence

MYBPC3
NM_000256.3 frameshift

Scores

Not classified

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:18

Conservation

PhyloP100: 2.20
Variant links:
Genes affected
MYBPC3 (HGNC:7551): (myosin binding protein C3) MYBPC3 encodes the cardiac isoform of myosin-binding protein C. Myosin-binding protein C is a myosin-associated protein found in the cross-bridge-bearing zone (C region) of A bands in striated muscle. MYBPC3 is expressed exclusively in heart muscle and is a key regulator of cardiac contraction. Mutations in this gene are a frequent cause of familial hypertrophic cardiomyopathy. [provided by RefSeq, May 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 18 ACMG points.

PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-47346638-GAA-G is Pathogenic according to our data. Variant chr11-47346638-GAA-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 42801.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-47346638-GAA-G is described in Lovd as [Pathogenic]. Variant chr11-47346638-GAA-G is described in Lovd as [Likely_pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
MYBPC3NM_000256.3 linkuse as main transcriptc.913_914del p.Phe305ProfsTer27 frameshift_variant 11/35 ENST00000545968.6

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
MYBPC3ENST00000545968.6 linkuse as main transcriptc.913_914del p.Phe305ProfsTer27 frameshift_variant 11/355 NM_000256.3 P4Q14896-1
MYBPC3ENST00000399249.6 linkuse as main transcriptc.913_914del p.Phe305ProfsTer27 frameshift_variant 10/345 A2
MYBPC3ENST00000544791.1 linkuse as main transcriptc.913_914del p.Phe305ProfsTer27 frameshift_variant, NMD_transcript_variant 11/275

Frequencies

GnomAD3 genomes
AF:
0.00000664
AC:
1
AN:
150494
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000148
Gnomad OTH
AF:
0.00
GnomAD4 exome
AF:
0.00000164
AC:
2
AN:
1217482
Hom.:
0
AF XY:
0.00000327
AC XY:
2
AN XY:
610872
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000221
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.00000664
AC:
1
AN:
150494
Hom.:
0
Cov.:
31
AF XY:
0.0000136
AC XY:
1
AN XY:
73440
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000148
Gnomad4 OTH
AF:
0.00

ClinVar

Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:18
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hypertrophic cardiomyopathy Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingCenter for Human Genetics, University of LeuvenOct 31, 2018- -
Pathogenic, no assertion criteria providedresearchRampazzo Lab, Human Molecular Genetics Unit, University of PaduaApr 18, 2017It is not found in 250 ethnically matched healthy controls (500 chromosomes), in dbSNP , in the 1000 Genomes Project database, in the Exome Variant Server or in the Exome Aggregation Consortium. We identified this mutation in 19 (19.5%) italian HCM patients (14 men and 5 women). Among 79 relatives belonging to 14 families, 45 resulted to be mutation carriers and 29 of them had phenotypical expression of HCM. A shared haplotype was found in all probands carrying the mutation, indicating that a common founder was likely in these families. -
Pathogenic, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineOct 26, 2023The p.Phe305ProfsX27 in MYBPC3 has been reported in >20 individuals with hypertrophic cardiomyopathy (HCM) and segregated with >10 affected relatives from >10 families (Olivotto 2008 PMID: 18533079, Millat 2010 PMID: 20800588, Marsiglia 2013 PMID: 24093860, Calore 2015 PMID: 25740977, LMM Data). This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 42801). It has been identified in 0.002% (1/67564) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 305 and leads to a premature termination codon 27 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the MYBPC3 gene is an established disease mechanism in autosomal dominant HCM. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PS4, PP1_Strong, PM2_Supporting, PVS1. -
Pathogenic, criteria provided, single submitterclinical testingInvitaeNov 21, 2023This sequence change creates a premature translational stop signal (p.Phe305Profs*27) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with hypertrophic cardiomyopathy (PMID: 18533079, 25740977, 27532257, 28794111). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 42801). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterresearchAgnes Ginges Centre for Molecular Cardiology, Centenary InstituteJan 20, 2017The MYBPC3 Phe305Profs*27 has been previously reported in mulitple HCM patients (Calore C, et al., 2015; Marsiglia JD, et al., 2013; Teirlinck CH, et al., 2012; Millat G, et al., 2010, Olivotto I, et al., 2008), and is an established Italian founder (Calore C, et al., 2015). This variant has not identified in the 1000 genomes project (http://www.1000genomes.org/), or in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/). Our lab has identified this variant in 2 HCM probands both of which are of Italian descent. 1 proband harbours a second variant (CRYAB 324+5G>T). Familial screening did not reveal a family history of disease or SCD, therefore the significance of the second variant (CRYAB 324+5G>T) is undetermined. Loss of function mutations in MYBPC3 are an established cause of HCM. Therefore, we classify MYBPC3 Phe305Profs*27 as "pathogenic". -
Hypertrophic cardiomyopathy 4 Pathogenic:4
Likely pathogenic, criteria provided, single submitterclinical testingLaboratory of Genetics and Molecular Cardiology, University of São Paulo-- -
Pathogenic, criteria provided, single submitterclinical testingCentre for Mendelian Genomics, University Medical Centre LjubljanaFeb 21, 2019This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. -
Pathogenic, criteria provided, single submitterclinical testingInstitute of Medical Genetics and Applied Genomics, University Hospital TübingenJan 24, 2024- -
Pathogenic, no assertion criteria providedliterature onlyOMIMMay 01, 2015- -
not provided Pathogenic:3
Pathogenic, criteria provided, single submitterclinical testingGeneDxMar 08, 2021Not observed in large population cohorts (Lek et al., 2016); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Reported in ClinVar as likely pathogenic/pathogenic by other clinical laboratories (ClinVar ID#42801; Landrum et al., 2016); This variant is associated with the following publications: (PMID: 25740977, 18533079, 20800588, 27532257, 28794111, 31513939, 28699631, 33673806) -
Pathogenic, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
Pathogenic, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Cardiomyopathy Pathogenic:2
Pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpApr 25, 2022Variant summary: MYBPC3 c.913_914delTT (p.Phe305ProfsX27) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 233482 control chromosomes (gnomAD). c.913_914delTT has been reported in the literature in multiple individuals affected with Cardiomyopathy (e.g. Calore_2015, Cecconi_2016, De Bortoli_2017). These data indicate that the variant is very likely to be associated with disease. Nine ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioJul 30, 2021- -
Hypertrophic cardiomyopathy 4;C3715165:Left ventricular noncompaction 10 Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsSep 27, 2021- -
Primary familial hypertrophic cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingBlueprint GeneticsAug 14, 2015- -
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsMay 26, 2023The c.913_914delTT pathogenic mutation, located in coding exon 11 of the MYBPC3 gene, results from a deletion of two nucleotides at nucleotide positions 913 to 914, causing a translational frameshift with a predicted alternate stop codon (p.F305Pfs*27). This variant has been detected in several individuals from hypertrophic cardiomyopathy cohorts, has shown segregation with disease in families, and has also been reported as an Italian founder mutation (Olivotto I et al. Mayo Clin. Proc., 2008 Jun;83:630-8; Marsiglia JD. Am. Heart J. 2013 Oct;166(4):775-82; Calore C et al. J. Med. Genet., 2015 May;52:338-47; Walsh R et al. Genet. Med., 2017 02;19:192-203). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
MYBPC3-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesJul 06, 2023The MYBPC3 c.913_914delTT variant is predicted to result in a frameshift and premature protein termination (p.Phe305Profs*27). This variant was reported in numerous individuals with hypertrophic cardiomyopathy (Olivotto et al. 2008. PubMed ID: 18533079; Table S1B, Walsh et al. 2017. PubMed ID: 27532257; Table S1, Robyns et al. 2020. PubMed ID: 31513939), and was considered an Italian founder variant (Calore et al. 2015. PubMed ID: 25740977). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in MYBPC3 are expected to be pathogenic. This variant is interpreted as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs397516080; hg19: chr11-47368189; API